Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:52 am EST
Share
Yuyu Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported negative sales was KRW 0.00044 million compared to KRW 0.00042 million a year ago. Net loss was KRW 2,085.78 million compared to KRW 586.25 million a year ago. Basic loss per share from continuing operations was KRW 130 compared to KRW 41 a year ago. Diluted loss per share from continuing operations was KRW 130 compared to KRW 41 a year ago. Basic loss per share was KRW 130 compared to KRW 41 a year ago.
For the nine months, sales was KRW 0.00041 million compared to negative sales of KRW 0.00001 million a year ago. Net loss was KRW 3,778.51 million compared to KRW 466.55 million a year ago. Basic loss per share from continuing operations was KRW 240 compared to KRW 43 a year ago. Diluted loss per share from continuing operations was KRW 240 compared to KRW 43 a year ago. Basic loss per share was KRW 240 compared to KRW 43 a year ago.
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
YUYU PHARMA, INC. 
